• DNDi logo
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Global Headquarters
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia/India
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
DNDi logo
  • DNDi logo
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Global Headquarters
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia/India
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Press releases

Network of experts calls for urgent boost to research and development of rapid tests for cutaneous leishmaniasis in Latin America

Home > Press releases

Network of experts calls for urgent boost to research and development of rapid tests for cutaneous leishmaniasis in Latin America

Laboratory assistant conducts analysis at laboratory in Peru
CARTAGENA DE INDIAS — 3 Aug 2022
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print
  • English
    • English
    • Español
    • Português

redeLEISH, the leishmaniasis research network, released a manifesto during the WorldLeish 7 international conference calling on the scientific community and health authorities to prioritize the need to develop simple diagnostic tools for cutaneous leishmaniasis (CL).

According to the World Health Organization (WHO), approximately one million people worldwide are affected by CL. People affected by the disease develop single or multiple lesions on different parts of the body, which leads to social stigma, psychological distress, and economic losses. Despite its broad geographic distribution and its devastating impact on vulnerable communities, research and development (R&D) for this type of leishmaniasis still attracts very little investment.

The lack of availability of adequate tools for the diagnosis of CL is one of the biggest challenges to reaching the target of eliminating this disease as a public health problem, as set in WHO’s Road Map for Neglected Tropical Diseases, 2021-2030.

‘The lack of rapid diagnostic tests that are highly effective, accessible and easy to use in primary care makes it difficult to detect and treat CL early, compounding the suffering of the people impacted by the disease,’ said Joelle Rode, Senior Leishmaniasis Clinical Project Manager at the Drugs for Neglected Diseases initiative (DNDi).

Experts signing the redeLEISH Manifesto at WorldLeish 7

In an effort to guide the development of rapid diagnostic tools, the Foundation for Innovative New Diagnostics (FIND) set forth with experts a target product profile (TPP) with the requirements for an ideal CL test. ‘The development of a rapid test guided by criteria consensually defined and agreed upon, and which may be implemented in low-resource environments, must be a priority for the scientific community, governments and donors,’ said Israel Cruz, Head of International Health at the National School of Public Health, Instituto de Salud Carlos III, and a FIND collaborator.

The TPP was recently reviewed and supported by the WHO Diagnostic Technical Advisory Group (DTAG) for Neglected Tropical Disease Diagnostics.

Released today during the 7th edition of WorldLeish, the world’s foremost scientific conference on leishmaniasis, the manifesto highlights the challenging environment in endemic countries and the urgent need for more incentives for R&D of diagnostic tests for CL. According to a report from G-FINDER, a mere USD 100,000 was invested in 2020 for R&D of diagnostic tools for leishmaniasis, representing less than 0.5% of global R&D investment for the disease (USD 45 million in total).

‘Through this manifesto, we researchers pledge to contribute to the creation of a common strategic agenda aiming at the production, validation, implementation and access to adequate new diagnostics tools for CL,’ said Glaucia Cota, Coordinator of the Leishmaniasis Reference Group at the Instituto René Rachou, from Brazil’s Fundação Oswaldo Cruz (FIOCRUZ).

Read the manifesto

About redeLEISH

redeLEISH brings together around 200 experts from 91 organizations around the world who are engaged in strengthening collaborations and maximizing R&D efforts for cutaneous leishmaniasis. Created in 2014, the initiative supports the implementation of clinical trials for the evaluation of new therapeutic tools for the leishmaniases, promotes the harmonization of criteria for the conduction of clinical trials, and facilitates the information sharing on treatments, diagnostics and research developments in CL. With representatives in 28 countries, the network operates through a virtual forum to assist in technical-scientific exchanges, publishing annual newsletters, and through in-person meetings that allow the identification of research priorities and the articulation of collaborative projects.

About DNDi

A not-for-profit research and development organization, DNDi works to deliver new treatments for neglected patients, those living with Chagas disease, sleeping sickness (human African trypanosomiasis), leishmaniasis, filarial infections, mycetoma, paediatric HIV, and hepatitis C. DNDi is also coordinating the ANTICOV clinical trial to find treatments for mild-to-moderate COVID-19 cases in low- and middle-income countries. Since its inception in 2003, DNDi has delivered twelve new treatments to date, including new drug combinations for kala-azar, two fixed-dose antimalarials, and DNDi’s first successfully developed new chemical entity, fexinidazole, approved in 2018 for the treatment of both stages of sleeping sickness. dndi.org

Media contact

DNDi
Marcela Dobarro
mdobarro@dndi.org
+55 21 981149429

Photo credit: Vinicius Berger – DNDi

Policy advocacy Cutaneous leishmaniasis

Read, watch, share

Loading...
Doctor with patient in hospital setting
News
15 Aug 2022

DNDi Media Workshop 2022 for Asian Science and Health Journalists

Viewpoints
12 Aug 2022

The climate crisis and infectious diseases: what role for DNDi?

From neglect to hope: Voices of leishmaniasis film poster
Videos
2 Aug 2022

From neglect to hope: Voices of leishmaniasis

Mother with her two children, Indian woman, and African doctor
Publications
1 Aug 2022

New hope for leishmaniasis

Lab activities
Press releases
27 Jul 2022

Korean cutting-edge technology to reduce the cost of promising drug for neglected disease visceral leishmaniasis

Statements
18 Jul 2022

DNDi‘s comments on the working draft of the WHO CAll for the consideration of the INB at its second meeting

Man standing by the river
Publications
15 Jul 2022

DNDi 2021 Annual Report

Lab activities
Press releases
6 Jul 2022

Wellcome renews partnership with DNDi to develop new generation drugs to treat leishmaniasis

VIEW ALL

Help neglected patients

To date, we have delivered twelve new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
DNDi logo
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
We use cookies to track our audience and improve our content. By clicking 'Accept All', you are agreeing to our use of cookies. Click on 'Customize' to accept only some cookies.
Customize
ACCEPT ALL
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-advertisement1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent1 yearRecords the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
elementorneverThis cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
PHPSESSIDsessionThis cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThe _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_16Q5RH3XRG2 yearsThis cookie is installed by Google Analytics.
_gat_UA-10302561-11 minuteA variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
_gid1 dayInstalled by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
_hjAbsoluteSessionInProgress30 minutesHotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
_hjFirstSeen30 minutesHotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
_hjIncludedInPageviewSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
_hjIncludedInSessionSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.
_hjSession_112884430 minutesNo description
CONSENT2 yearsYouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
Targeting
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
CookieDurationDescription
_hjSessionUser_11288441 yearNo description
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
SAVE & ACCEPT
Powered by CookieYes Logo